Correction to Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (The Lancet Oncology (2018) 19(11) (1480–1492)(S1470204518307009)(10.1016/S1470-2045(18)30700-9));Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

The Lancet Oncology

Volumn 19, Issue 11, 2018, Pages 1480-1492

  Hodi, Frank Stephen ^a   Chiarion Sileni, Vanna ^b   Gonzalez, Rene ^c   Grob, Jean Jacques ^d   Rutkowski, Piotr ^e   Cowey, Charles Lance ^f   Lao, Christopher D ^g   Schadendorf, Dirk ^h,i   Wagstaff, John ^j   Dummer, Reinhard ^k   Ferrucci, Pier Francesco ^l   Smylie, Michael ^m   Hill, Andrew ⁿ   Hogg, David ^o   Marquez Rodas, Ivan ^p   Jiang, Joel ^q   Rizzo, Jasmine ^q   Larkin, James ^r   Wolchok, Jedd D ^s,t  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d TIMONE HOSPITAL   (France)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h UNIVERSITY OF DUISBURG ESSEN   (Germany)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j SWANSEA UNIVERSITY   (United Kingdom)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^m CROSS CANCER INSTITUTE   (Canada)

ⁿ Tasman Oncology Research Ltd   (Australia)

^o PRINCESS MARGARET HOSPITAL   (Canada)

^p HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^q BRISTOL MYERS SQUIBB   (United States)

^r INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^s MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^t WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; IPILIMUMAB; NIVOLUMAB; PLACEBO; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; ARTHRALGIA; ARTICLE; BRAF GENE; CANCER PATIENT; CANCER STAGING; COLITIS; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FOLLOW UP; GENE MUTATION; HEADACHE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; INTENTION TO TREAT ANALYSIS; LIVER TOXICITY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; VITILIGO; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; MORTALITY; MUTATION; PATHOLOGY; SECONDARY; SKIN TUMOR; TIME FACTOR;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DOUBLE-BLIND METHOD; HUMANS; IPILIMUMAB; MELANOMA; MUTATION; NEOPLASM STAGING; NIVOLUMAB; PROGRESSION-FREE SURVIVAL; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TIME FACTORS;

EID: 85056160653     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30841-6     Document Type: Erratum

References (17)

1. Garbe, C, Eigentler, TK, Keilholz, U, Hauschild, A, Kirkwood, JM, Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16 (2011), 5–24.
2. Schadendorf, D, Hodi, FS, Robert, C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
3. Chapman, PB, Ascierto, PA, Schadendorf, D, et al. Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAFV600-mutant melanoma. J Clin Oncol, 35(suppl 15), 2017, 9526 (abstr).
4. V600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol 28 (2017), 2581–2587.
5. Postow, MA, Callahan, MK, Wolchok, JD, Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
6. Wolchok, JD, Chiarion-Sileni, V, Gonzalez, R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377 (2017), 1345–1356.
7. Schachter, J, Ribas, A, Long, GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390 (2017), 1853–1862.
8. Long, GV, Schachter, J, Ribas, A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2 years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. J Clin Oncol, 36(suppl), 2018, 9503 (abstr).
9. Long, GV, Flaherty, KT, Stroyakovskiy, D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28 (2017), 1631–1639.
10. Dummer, R, Ascierto, PA, Gogas, H, et al. Overall survival in COLUMBUS: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. J Clin Oncol, 36(suppl 15), 2018, 9504 (abstr).
11. Hodi, FS, Chesney, J, Pavlick, AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomized, controlled, phase 2 trial. Lancet Oncol 17 (2016), 1558–1568.
12. Schadendorf, D, Wolchok, JD, Hodi, FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35 (2017), 3807–3814.
13. Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
14. Linden, A, Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis. J Eval Clin Pract 12 (2006), 132–139.
15. Heagerty, PJ, Lumley, T, Pepe, MS, Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56 (2000), 337–344.
16. Long, GV, Eroglu, Z, Infante, J, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol 36 (2018), 667–673.
17. Pollack, MH, Betof, A, Dearden, H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29 (2018), 250–255.